New Evidence From Cardiorenal Outcomes Flashcards
Describe the VERTIS CV study.
The VERTIS CV study evaluated the efficacy and safety of ertugliflozin in people with established cardiovascular disease (CVD) and type 2 diabetes. It found that ertugliflozin was similar to placebo in terms of the primary outcome and key secondary outcomes, except for heart failure hospitalization (HHF).
What were the findings of the CREDENCE study?
The CREDENCE study showed that canagliflozin treatment significantly reduced the risk of progression to renal replacement therapy, low eGFR, doubling of serum creatinine level, or death from cardiovascular or kidney causes in adults with type 2 diabetes and nephropathy.
Describe the DAPA-CKD trial.
The DAPA-CKD trial assessed the effects of dapagliflozin on kidney outcomes in participants with and without type 2 diabetes and chronic kidney disease. It demonstrated a clear benefit of dapagliflozin on kidney outcomes and cardiovascular death or heart failure hospitalization.
What were the results of the SCORED trial?
The SCORED trial evaluated the effects of sotagliflozin in people with type 2 diabetes, moderate renal impairment, and cardiovascular risk factors. It found that sotagliflozin reduced the composite endpoint of cardiovascular mortality, heart failure hospitalization, or urgent visits for heart failure, but had no effect on the composite kidney endpoint.
What were the findings of the EMPEROR-Reduced trial?
The EMPEROR-Reduced trial showed that empagliflozin reduced the risk of cardiovascular mortality or heart failure hospitalization in people with heart failure and reduced ejection fraction, regardless of the presence of type 2 diabetes.
Describe the SOLOIST-WHF trial.
The SOLOIST-WHF trial demonstrated that sotagliflozin reduced the total number of cardiovascular deaths or hospitalizations or urgent visits for heart failure in people with type 2 diabetes and worsening heart failure, regardless of ejection fraction.
What were the findings of the AMPLITUDE-O trial?
The AMPLITUDE-O trial showed that weekly efpeglenatide had a beneficial effect on major adverse cardiovascular events (MACE) and a composite kidney outcome in people with type 2 diabetes.
What were the results of the ITCA 650 trial?
The ITCA 650 trial found that the osmotic minipump delivering exenatide subcutaneously had a neutral effect on MACE compared to placebo in individuals with type 2 diabetes at high risk for cardiovascular disease.
What is being assessed in the ongoing SURPASS-CVOT trial?
The ongoing SURPASS-CVOT trial is assessing the cardiovascular effects of tirzepatide, with dulaglutide as an active comparator.
Describe the potential benefits of combined treatment with an SGLT2i and a GLP-1 RA.
Evidence suggests that combined treatment with an SGLT2i and a GLP-1 RA may reduce all-cause mortality rates, attenuate the decline in eGFR, and improve outcomes in people with type 2 diabetes.
What did the post hoc analysis of the EXSCEL study suggest?
The post hoc analysis of the EXSCEL study suggested that the combination of exenatide once weekly (EQW) plus an SGLT2i reduces all-cause mortality rates and attenuates the decline in eGFR compared to treatment with EQW alone.
What were the findings of the AMPLITUDE-O trial regarding GLP-1 RA treatment with or without an SGLT2i?
The AMPLITUDE-O trial found comparable benefits of GLP-1 RA treatment in participants receiving an SGLT2i as background therapy and those who were not.
What were the inclusion criteria for the VERTIS CV study?
The VERTIS CV study exclusively recruited people with established cardiovascular disease (CVD) and type 2 diabetes.
What were the inclusion criteria for the VERTIS CV study?
The VERTIS CV study exclusively recruited people with established cardiovascular disease (CVD) and type 2 diabetes.
What were the inclusion criteria for the CREDENCE study?
The CREDENCE study included adults with type 2 diabetes, an eGFR from 30 to <90 ml/min per 1.73 m2, and albuminuria (30–500 mg/mmol [300–5,000 mg/g] creatinine).
